ASX Announcement

24 June 2022

Antisense Therapeutics to Present at the Parent Project Muscular Dystrophy Annual Conference 2022

Antisense Therapeutics [ASX: ANP | US OTC: ATHJY | FSE: AWY], (the Company) an Australian biopharmaceutical company developing and commercializing antisense pharmaceuticals for unmet need in rare diseases, including Duchenne muscular dystrophy (DMD) is pleased to advise that Dr Gil Price, MD, Antisense Therapeutics' US-based Board member & Consultant Medical Director, will give a presentation at the PPMD's Annual Conference 2022 which is being held from June 23 to June 26, 2022 in Scottsdale Arizona, US.

Dr Price will present on the Company's lead development program, ATL1102 for DMD, during the session on the "Strategies for Mitigating Inflammation and Fibrosis" panel at 11.20am, 24 June (MST): 4.30am 25 June (AEST).

For more information or to access the live streaming or recording of the conference, people can register on PPMD's website by clicking here. Otherwise, all presentations from the Conference will be available for download within a couple of weeks after the Conference.

For more information please contact:

Antisense Therapeutics
Mark Diamond
Managing Director and CEO
+61 (0)3 9827 8999
www.antisense.com.au

Investment Enquiries
Gennadi Koutchin
XEC Partners
gkoutchin@xecpartners.com.au
1300 932 037

US/European IR & Media
Laine Yonker/Joe Green
Edison Investor Relations
lyonker@edisongroup.com
+1 646-653-7035

This announcement has been authorised for release by the Board

About PPMD and the 2022 Annual Conference

"Parent Project Muscular Dystrophy fights to end Duchenne. We accelerate research, raise our voices to impact policy, demand optimal care for every single family, and strive to ensure access to approved therapies. Now in its 28th year, PPMD's Annual Conference has grown to be recognized worldwide as the foremost Duchenne muscular dystrophy meeting. Families, physicians, researchers, caregivers, industry partners and those living with Duchenne and Becker gather to connect, share information, and learn the latest progress in the fight to end Duchenne." For more information please visit **here**.

About Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] is an Australian publicly listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne muscular dystrophy (DMD) patients and reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.